Pharmaceutical Technology

NOVEMBER 24, 2022

Understanding how a drug will act in the body, including how it is absorbed, distributed, and eventually eliminated, is a crucial component of drug research. Well-planned ADME investigations are conducted in the early stages of clinical research to generate this important data, which is needed for regulatory submissions.

Bioavailability 130

Bioavailability Manufacturing Drugs Production 130

Outsourcing Pharma

JANUARY 24, 2023

Evidence shows that animal models currently dominating bioavailability estimates are poor predictors and human, cell-based multi-organ microphysiological systems (MPS) should be investigated, CN Bio says.

Bioavailability 52

Bioavailability Research Clinical Development Development 52

Scienmag

MAY 21, 2022

By measuring the maximum concentration over time, the researchers found bioavailability of vitamin D […].

Bioavailability 58

Bioavailability Research 58

Pharmaceutical Technology

DECEMBER 19, 2022

This question forms the basis of a new scientific research paper, Nanomilling and size characterization of highly concentrated API suspensions from Fribourg University, Switzerland, which details experiments using nanomilling techniques to reduce micron sized particles further down to nanometric size, thus useful for the pharmaceutical industry.

Production 130

Production Bioavailability Biohazard Biohazard 130

XTalks

JUNE 27, 2024

Therefore, techniques and technologies that promote drug solubility and bioavailability are in high demand. Their focus is on improving drug solubility and bioavailability with powerful amorphous dispersion technologies, such as KinetiSol for poorly soluble compounds.

Bioavailability 59

Bioavailability Manufacturing Drugs Development 59

pharmaphorum

JULY 22, 2021

Arvinas has previously signed PROTAC-based research collaborations with Bayer , Roche’s Genentech unit and Merck & Co/MSD although the latter deal expired last year. The company said other companies were also looking at the orally bioavailable drug, but Pfizer emerged as an ideal partner for ARV-371.

Protein 116

Protein Hormones Bioavailability Drugs 116

Camargo

JULY 8, 2021

Researchers at the Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have observed that MAOIs might help the immune system attack cancer. The FDA itself did not produce the assessment but instead contracted the Eastern Research Group to conduct the assessment and produce a report. . ” .

Development 130

Development Bioequivalency Gene Expression Drugs 130

Pharmaceutical Technology

JANUARY 25, 2023

According to a whitepaper from contract research, development and manufacturing organisation Syngene, PROTACs are effective against “undruggable” targets such as transcription factors, and scaffolding proteins that cannot be otherwise targeted by the traditional small molecule inhibitors.

Protein 130

Protein Bioavailability Development Scientist 130

XTalks

OCTOBER 2, 2024

With positive outcomes in preclinical models, EB-003 has confirmed oral bioavailability, adding to its therapeutic potential. The WFMH encourages participation in their “Voices of the Workplace” initiative. Their platform seeks to unite diverse communities worldwide through shared experiences, solutions and impactful narratives.

Research 52

Research Bioavailability Trials Hormones 52

Camargo

DECEMBER 22, 2021

Pediatric Research Equity Act (PREA) Requirements. Clinical pharmacology may also involve comparative bioavailability analyses, which are generally required for drug formulation bridging studies, to demonstrate bioequivalence. Biowaiver Eligibility.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

XTalks

FEBRUARY 25, 2022

After five years of research and development, the brand found a way to transform saved grain from brewing into nutrient-rich, barley-based proteins and fibers that have a variety of applications in the food and beverage industry. billion by 2027 at a compound annual growth rate (CAGR) of two percent, according to Research and Markets.

Production 98

Production Protein Branding Bioavailability 98

The Pharma Data

JANUARY 7, 2021

The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. Emerging Technology Needs and Value Proposition for Strategic Partnerships with Contract Development and Manufacturing Organizations (CDMOs).

Bioavailability 52

Bioavailability Production Manufacturing Drugs 52

Cloudbyz

MARCH 5, 2024

The complexities in clinical research in both Clinical research for both biologics and small molecules involves complex processes that are crucial for demonstrating safety, efficacy, and quality before obtaining regulatory approval. Enhancing bioavailability is often a key focus in the development of small molecule drugs.

Development 97

Development Drugs Immune Response Manufacturing 97

Pharmaceutical Technology

MARCH 21, 2023

But according to GlobalData, medical cannabis research is set to escalate. So far, the FDA has approved just one CBD product, a prescription drug designed to treat seizures associated with Lennox Gastaut syndrome (LGS) [i].

Production 243

Production Bioavailability Pharmacy Clinical Trials 243

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. Session Category: Clinical Research (Excluding Trials). Abstract Number: 442.

Research 52

Research Clinical Trials Clinical Trials Trials 52

The Pharma Data

APRIL 7, 2023

CycPeptMPDB, a novel database – created by Tokyo Tech researchers – focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. That is why, in recent years, cyclic peptides have become a very active research area.

Drugs 40

Drugs Protein Bioavailability Research 40

Pharmaceutical Technology

FEBRUARY 13, 2023

However, there is a high level of attrition during the pharmaceutical research and development process, which is an indicator of the vast number of potential drug substances considered for progression. Quotient Sciences was asked to select the best candidate based on material science and oral bioavailability considerations.

Development 130

Development In-Vivo Drugs Clinical Trials 130

pharmaphorum

JANUARY 29, 2021

While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable. The new drug has already cleared phase 1 single and multiple ascending dose and clinical pharmacology studies, according to Lilly.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

pharmaphorum

NOVEMBER 9, 2022

This novel pathological mechanism is being targeted by NRG and was identified by the company’s collaborator, Professor Seth Masters of Melbourne, Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI). Following the Series A financing, Professor Masters joins NRG’s management team as vice president of discovery biology.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Roots Analysis

MARCH 1, 2022

This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration. Based on our research maximum number of players are located in North America (80%), followed by Europe and Asia-Pacific & RoW (5%, each).

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Bioavailability 52

Roots Analysis

MARCH 2, 2022

However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Oral Protein / Peptide-based Drugs.

Protein 52

Protein Drugs Drug Delivery Drug Delivery Systems 52

The Pharma Data

JULY 12, 2021

“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir.

Clinical Trials 52

Clinical Trials Clinical Trials Bioavailability Trials 52

The Pharma Data

NOVEMBER 11, 2020

As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About SLV213. About Selva Therapeutics.

Protein 52

Protein Bioavailability Development Drugs 52

The Pharma Data

MARCH 8, 2021

“We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

Pharmaceutical Technology

JUNE 26, 2022

Understanding the polymorphism of a drug compound plays a key role in both drug substance and drug product development, because it can negatively impact the downstream stability, solubility, and bioavailability of a drug.

Manufacturing 130

Manufacturing Drugs Production Development 130

XTalks

SEPTEMBER 24, 2024

With no cure currently available, managing symptoms and improving the quality of life for patients remain critical goals for medical research and treatment. This magazine immerses you in a world where industry leaders, patient advocates and top researchers converge to provide the most insightful perspectives on clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

Delveinsight

FEBRUARY 16, 2021

Maribavir is an orally bioavailable anti-CMV compound. The post Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev appeared first on DelveInsight Business Research.

Marketing 52

Marketing Protein Bioavailability Drugs 52

Delveinsight

JANUARY 7, 2021

Omega Funds led the series B round with assists from fellow new investor Fidelity Management & Research and existing backers Atlas Venture, OrbiMed, and Bristol Myers Squibb, which became involved through its Celgene acquisition. The progress has set Ikena to raise USD 120 million. Hologic acquires Biotheranostics for USD 230 Million.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

OCTOBER 15, 2020

From years of research on the proteasome system and key discoveries about its assembly, Cullgen’s founders have already demonstrated that the underlying technology can rapidly generate a large number of highly potent, selective, and bioavailable compounds.

Protein 40

Protein Medicine Bioavailability Development 40

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Significance: Pirfenidone might have a differential effect on FVC change in patients with uILD depending on baseline concomitant MMF treatment status-further research is required. Ofev (Nintedanib) Facts.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. The company employs 8 people and is supported by BPI France, the National Research Agency and Eurasanté.

Drugs 40

Drugs Protein Bioavailability Development 40

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. Consider targeting your therapies that fail to be orally bioavailable and brain penetrant. Viral Vectors for Gene Delivery to the CNS. The patients are waiting!

Trials 83

Trials Drug Delivery Drugs Gene 83

Roots Analysis

SEPTEMBER 1, 2023

Real World Data and Blue Ocean Strategy Real-world data is particularly useful for researchers, as it provides valuable insights from patient data and knowledge that can impact many decision-making processes. New Drug Formulations as a Blue Ocean Strategy New drug formulations can help improve patient adherence and reduce side effects.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

The Pharma Data

JANUARY 27, 2021

” Vektor is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. . “The addition of scalable in-house manufacturing capability creates the potential for significant growth across virtually all of our development and commercialization programs.”

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

The Pharma Data

NOVEMBER 19, 2020

These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. The Company has created a covid19@soseiheptares.com contact address for companies and researchers who would like to discuss possible collaborations.

Development 40

Development Bioavailability Production Drugs 40

Delveinsight

JULY 30, 2020

A novel, brain penetrant, orally bioavailable and selective PPAR? The post A Complex Chromosomal Abberation Called Adrenoleukodystrophy appeared first on DelveInsight Business Research. agonist, Leriglitazone has received Orphan Drug Designation from the EMA and the FDA and has also been granted FDA fast-track procedure in X-ALD.

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

DECEMBER 1, 2020

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” said Evan N. With origins in AI research at Stanford University by its co-founder and CEO, Evan Feinberg, Ph.D.,

Development 40

Development Drugs Engineer FDA Approval 40